BeOne Medicines (49BA) Q2 2026 Earnings Report

The call presented a strongly positive commercial and financial picture: robust revenue and EPS growth, raised full‑year guidance, doubled free cash flow, high gross margins, and multiple meaningful regulatory and late‑stage pipeline milestones (MANGROVE result, BEQALZI approval, BTK degrader progress). Headwinds and uncertainties were present but limited relative to the strength described — including a missed uMRD superiority in CELESTIAL‑301 (though PFS remains the primary endpoint), a $60 million tax settlement, increased operating expense guidance to fund pipeline investment, and ongoing competitive dynamics. On balance, the company emphasized durable demand for BRUKINSA, expanding global footprint, and an accelerating late‑stage pipeline, leading to an overall favorable outlook.

Management raised 2026 guidance, increasing revenue by $300 million to a new range of $6.6–$6.8 billion and boosting GAAP operating income by $250 million to $1.0–$1.1 billion (non‑GAAP operating income now $1.7–$1.8 billion); they expect full‑year gross margin in the high‑80% range and set operating expenses at $4.8–$5.0 billion to fund commercial and pipeline investments (with 2027 OPEX growth expected roughly in line with the past two years). For context from Q2, they reported $1.7 billion revenue, $1.5 billion gross profit (just under 90% gross margin), $1.2 billion operating expenses, $325 million operating income, $237 million net income, GAAP EPS $2.05, adjusted operating income $503 million, adjusted net income $444 million, adjusted diluted EPS $3.84, and free cash flow of $435 million.